An interventional study of Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation in Atrial Fibrillation, sponsored by Tor Biering-Sørensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.
Sponsored by Tor Biering-Sørensen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Atrial Fibrillation with a site in Denmark — 31 open to participants now, 48 under way, 3 of them phase 3. Atrial Fibrillation · Denmark.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, this one is the 41st largest by planned enrollment of the 140 interventional ones that give a count, is one of 16 that started in 2024, is one of 73 with no phase, reaches primary completion later than 38 of the 47 other live ones, and was the 142nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →31 of the 176 studies in Atrial Fibrillation with a site in Denmark are open now. Recruiting first, the newest first:
University College Copenhagen · Sites in Denmark
Ages 18+
Abbott Medical Devices · Sites in Denmark, Belgium, Czechia and 7 more countries
Ages 18+
Acesion Pharma · Sites in Denmark, Bulgaria, Germany and 5 more countries
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
University of L'Aquila · Sites in Denmark, Croatia, Egypt and 12 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 17 · Phase 3 32 · Phase 4 19
First in 1999; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 852 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 273 across the 140 interventional studies, 391 across the 36 observational. Of the 118 that completed or were terminated, 40 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 176 have an industry lead sponsor. The 10 most frequent:
Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.
Tor Biering-Sørensen has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
15 of the studies in Atrial Fibrillation with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT03862859Nicholas CarlsonThe Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | 2027-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, controlled trial is to investigate whether coronary computed tomography (CT) angiography prior to catheter ablation and derived treatment (medical anti-ischemic and multimodality treatment and/or mechanical revascularization) can improve clinical outcomes in patients with atrial fibrillation undergoing catheter ablation.
A sub-study will investigate the effect of different ablation strategies on clinical outcomes in patients with atrial fibrillation undergoing catheter ablation.
The study is an investigator-initiated, prospective, randomized, unblinded, controlled trial to investigate whether coronary CT angiography prior to catheter ablation and derived treatment can improve clinical outcomes in patients with atrial fibrillation undergoing catheter ablation. The study population will consist of approximately 852 patients aged 18 years and above referred for a catheter ablation treatment for atrial fibrillation at Gentofte Hospital in Denmark. All participants included in the study will have a coronary CT angiography and coronary artery calcium (CAC) scoring performed as an amendment to the standard CT scan of the heart for mapping of the atria prior to catheter ablation. The participants are randomized 1:1 to either have the coronary CT angiography analyzed or not at the time of catheter ablation. According to the results of the coronary CT angiography in the intervention group, subsequent actions may include intensified multimodality medical treatment or referral to further functional imaging or invasive coronary angiography and possibly mechanical revascularization according to clinical guidelines. The study will be completed when each patient has been followed for at least 1 year. After ablation, an insertable cardiac monitor will be implanted in participants to monitor the heart rhythm continuously throughout the study period.The primary endpoint is time to first documented recurrence of atrial tachyarrhythmia lasting >30 seconds between 91 days after ablation and end of follow-up.
All participants meeting the eligibility criteria and enrolled in the FIBCAG main study are eligible to participate in a sub-study with the purpose of investigating different catheter ablation strategies by sub-randomizing participants to different ablation protocols depending on whether they have paroxysmal or persistent atrial fibrillation or they are undergoing first or redo ablation:
All ablation procedures and strategies are currently standard interventions in clinical care. Procedures are performed under general anesthesia or deep sedation based on availability, and patients are blinded to the method of ablation. PVI will be performed according to best current clinical practice using pulsed field ablation with a single shot device or by point-by-point ablation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on the results of the coronary CT angiography and CAC scoring in the intervention group, relevant anti-ischemic and multimodality treatment will be initiated according to clinical guidelines.
Diagnostic Test: Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation
Patients in the control group will follow the current standard of care prior to ablation.
Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
Between-group difference in time to first recurrence of atrial tachyarrhythmia lasting >30 seconds between 91 days after ablation and end of follow-up.
Time frame: Up to 4 years
Between-group difference in time to first documented occurrence of other arrhythmias after ablation
Time frame: Up to 4 years
Between-group difference in AF burden as registered by the implantable cardiac monitor after ablation
Time frame: Up to 4 years
Between-group difference in the number of participants hospitalized for angina pectoris or acute coronary syndrome after ablation
Time frame: Up to 4 years
Between-group difference in the incidence of acute myocardial infarction after ablation
Time frame: Up to 4 years
Between-group difference in the number of patients undergoing revascularization procedures after ablation
Time frame: Up to 4 years
Between-group difference in the number of deaths due to cardiovascular disease after ablation
Time frame: Up to 4 years
Between-group difference in incidence of stroke after ablation
Time frame: Up to 4 years
Between-group difference in incidence of heart failure or heart failure hospitalization after ablation
Time frame: Up to 4 years
Between-group difference in number of participants hospitalized for atrial fibrillation or other atrial tachyarrythmias after a 3-month blanking period after ablation
Time frame: Up to 4 years
Number of cardioversions, repeat ablations, and new-onset antiarrythmic drug treatment after a 3-month blanking period after catheter ablation.
Time frame: Up to 4 years
Between-group difference in the prevalence of coronary artery disease in patients with atrial fibrillation at baseline
Time frame: 0
Between group difference in the quality of life of participants as quantified by a validated self-administered questionnaire
Time frame: 1 year
The proportion of participants in the active arm that are started or intensified on the following medication following the coronary CT angiography: statins, antithrombotic or antidiabetic medication
Time frame: 1 month
Between-group differences in the proportion of patients that are started or intensified on the following medication within 1 year after the coronary CT angiography: statins, antithrombotic, antidiabetic, or antihypertensive medication.
Time frame: 1 year
Between-group difference in the number of patients compliant with their prescribed medication 1 and 2 years after the coronary CT angiography as assessed based on a self-administered questionnaire
Time frame: Up to 2 years
Plan to share: Yes — Please contact the sponsor-investigator in case of any inquiries.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Apr 2028, 48 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tor Biering-Sørensen